In this month’s issue, we continue the exploration of Medicine 3.0, the next-generation of cutting-edge practices that patients need to adopt if we wish to maximize our healthspan as well as our lifespan. By being proactive, informed, and by taking concrete action, Erez Kalir writes, we can add both years to our lives, and life to our years.
This coming January will mark two years since we launched Tech Frontiers and its predecessor, Biotech Frontiers. During that time, we’ve compiled an extraordinary track record: Eight of our recommendations have appreciated over 100% and many others have appreciated at least 50%. In the meantime, in our biotech portfolio, we encountered only two meaningful losers
China’s artificial intelligence sector is not in a market bubble. In fact, the company Erez Kalir recommends this month trades at a significantly lower valuation than its U.S. peers and is poised to soar going forward.
If you’ve missed out on Bitcoin’s and Ethereum’s meteoric rise, this month’s issue of Tech Frontiers is for you. If you’ve ridden these meteors, congratulations – this issue will offer you a thoughtful way to diversify your gains and stay onboard.
Shares of the Tech Frontiers July recommendation, Prime Medicine (Nasdaq: PRME), are trading at around $6.37 today, a gain of over 100% from our entry price of $3.07 three months ago. As a result, we recommend selling half your position. Prime is making terrific progress advancing its gene-editing platform and we have many reasons for
Last week, Fortress Biotech (Nasdaq: FBIO) issued a press release disclosing that the Food And Drug Administration (“FDA”) had issued a Complete Response Letter (“CRL”) for CUTX-101, Fortress’s new drug to treat Menkes disease. A CRL is the FDA’s way of communicating it has decided against approving a new drug application in its current form.
Yesterday, aTyr Pharma (Nasdaq: ATYR) reported that its Phase 3 trial of efzofitimod in pulmonary sarcoidosis failed to meet its primary endpoint. The study’s results were doomed by a much higher-than-expected placebo effect, making it impossible for efzofitimod to attain the statistically significant differentiation relative to placebo needed for the trial’s success. Shares of aTyr
In the inaugural issue of Tech Frontiers, our first recommendation is a company that sits at the intersection of biotech and AI. It’s a small company – which has a major upcoming catalyst only weeks away – is also poised to be super-charged by AI.
Unlike first generation gene editing tools based on CRISPR technology, this new one, prime editing, doesn’t make breaks in DNA’s double helix. Instead, it uses a guided search-and-replace mechanism – like a molecular word processor – to correct typos in our genetic code. And the big name investors are pouring in.
